Meet Image Analysis Group in Boston!
Image Analysis Group (IAG), a leading medical imaging company, is proud to announce its participation in the 11th Annual IO360° Summit in Boston, taking place from March 24-26, 2025.
Dr. Olga Kubassova, Founder and President of IAG, will be a featured panelist in the session “AI’s Role in Advancing Immuno-Oncology R&D Strategies” on March 25th at 2:25 pm. Dr. Kubassova will share insights on how artificial intelligence is transforming immuno-oncology research, including:
-
Identifying novel pathways in the tumor microenvironment
-
Optimizing immune therapies such as ADCs, cancer vaccines, and CAR T-cells
-
Accelerating drug discovery and reshaping R&D methodologies
Visitors to IAG’s booth #18 will have the opportunity to experience DYNAMIKA V7, our cloud-native intelligent enterprise workflow solution for clinical trials. Recently awarded in the Innovation Category of the 2024 Pharmaceutical Technology Excellence Awards, DYNAMIKA integrates automated workflows and AI to enhance trial efficiency, streamline global data management, and ensure robust security measures.
IAG brings extensive experience in advanced imaging and its application to drug development, particularly in immunology and immuno-oncology. Our team has worked closely with leading pharmaceutical and biotech companies to provide critical imaging services and data analysis, enabling:
-
Early efficacy readouts using AI-driven methodologies
-
Comprehensive exploration of drug efficacy
-
Differentiation between pseudo-progression and true disease progression
-
Strategic collaborations that are transforming business models in immuno-oncology.
“We are excited to showcase our latest advancements in imaging analytics and AI-driven solutions at IO360°,” said Dr. Kubassova. “Our team looks forward to engaging with industry leaders and demonstrating how IAG’s expertise can accelerate the development of life-changing therapies in immuno-oncology.”
About Image Analysis Group (IAG)
IAG is a unique partner to life sciences companies, leveraging expertise in medical imaging and the power of DYNAMIKA to de-risk clinical development and deliver lifesaving therapies to patients sooner. IAG provides early drug efficacy assessments, smart patient recruitment, and predictive analysis of advanced treatment manifestations, lowering investment risk and accelerating study outcomes.